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1. Introduction 
To ensure a fruitful and healthy pregnancy, every maternal organ system needs to adapt to 
the novel physiological needs raised by the developing fetus. The maternal immune system 
is no exception. Since the conceptus is half of foreign origins, presenting paternal antigens, it 
is considered a semi-allograft to maternal immunity. Therefore, an immune tolerance must 
develop to avoid immunological rejection of the fetus. In the normal course of pregnancy, 
the mother extends her ‘definition of self’ for 40 weeks on the foreign antigens of the fetus, 
and the conceptus is accepted by the mother’s immune system. The impairment of this 
tolerance and the development of an abnormal immune response directed at the fetus play a 
major role in adverse pregnancy outcomes, including spontaneous abortion, preterm labour 
and preeclampsia. In recurrent abortion and preeclampsia, abnormal maternal immune 
reactions have an autoimmune character, and the disorders resemble many features 
typically seen in autoimmune diseases, or in association with autoimmune reactions. 
Although this does not mean that recurrent abortion or preeclampsia should be considered 
autoimmune conditions, it still suggests that abnormal autoimmune processes play an 
important role in their pathogenesis. In this regard, preeclampsia mimics autoimmune 
responses observed in both allograft rejection and graft-versus-host disease. 
Several aspects of the development of the pregnancy-specific immune tolerance have been 
described recently. Initially, the contact between maternal and fetal cells is taking place on a 
local level and is restricted to the decidua, but during the second trimester of pregnancy, it is 
extended to the entire body of the mother. Both the innate and adaptive arms of immunity 
are involved in these events. In this chapter we will focus on the role of T lymphocytes, the 
adaptive cellular elements of the immune system. We will discuss the characteristic 
alterations of T lymphocyte subsets in prevalence and functionality in healthy and 
pathologic development of the immune tolerance in human pregnancy. 
2. Th1 and Th2 cells 
T helper (Th) lymphocytes are traditionally classified into the Th1 and Th2 subsets based on 
their cytokine production pattern (Romagnani, 1991). The most important cytokines 
produced by Th1 cells are interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α) and 
interferon-γ (IFN-γ). Considered to be the main effectors of phagocyte-induced host defense, 
these cells are highly protective against infections sustained by intracellular agents. On the 
 
Autoimmune Disorders – Pathogenetic Aspects 
 
448 
other hand, Th2 cells produce IL-4, which stimulates IgE and IgG1 antibody production, IL-
5, which promotes the growth and differentiation of eosinophils, and IL-10 and IL-13, which 
together with IL-4 inhibit macrophage functions. The Th2 subset is mainly responsible for 
phagocyte-independent host defense, for example against helminthic infections. 
For many years, it was hypothesized that normal pregnancy induces a shift from Th1 
immunity towards Th2 immunity. However, it has been demonstrated recently that the 
levels of particular Th1 cytokines are raised, instead of lowered in normal pregnancy 
compared with the non-pregnant state (Challis et al., 2009). Current findings indicate that 
gravidity is both a pro-inflammatory and an anti-inflammatory condition, depending upon 
the stage of gestation. Grossly, pregnancy has three distinct immunological phases. The 
events of implantation and the first trimester require a strong inflammatory response to 
ensure the adequate remodelling of the uterine epithelium and the removal of cellular 
debris following the implantation of the blastocyst. Therefore, healthy pregnancy cannot be 
regarded as merely a state of relative immunosuppression, as once thought. On the contrary, 
by means of various cytokines, successful implantation is dependent upon the active 
contribution of the maternal immune system to stimulate adequate invasion of the 
trophoblastic tissue into the maternal uterine wall. Thus, the first trimester of pregnancy is 
hallmarked by pro-inflammatory events. The second immunological phase of gravidity 
consists of the second and third trimesters. This is the period of fetal growth and 
development, when an anti-inflammatory state is established. Finally, delivery represents 
the third immunological phase of pregnancy, when pro-inflammatory events dominate 
again and promote uterinal contractions to deliver the fetus and the placenta (Mor & 
Cardenas, 2010). 
IFN-γ appears to be a key cytokine in the regulation of pregnancy related inflammatory 
events. Under pathologic conditions with insufficient immune tolerance such as in 
preeclampsia, IFN-γ production is significantly increased compared with healthy pregnancy 
(Piccinni, 2010). In mice, it was reported that IL-4, IL-5 and IL-10 are detectable at the 
fetomaternal interface during all periods of gestation, whereas the presence of IFN-γ is 
transient, being detectable only in the first period (Lin et al., 1993; Wegmann et al., 1993). 
Although decidual NK cells are able to produce IFN-γ (Ashkar et al., 1998), they do not have 
a central role in fetal allograft rejection, since they do not express receptors specific for 
antigens and thus are not sensitive for the presence of paternal alloantigens. The significance 
of local Th2-type cytokine production in the decidua has been observed in humans as well. 
Piccinni et al. measured cytokine production in decidual CD4 cells isolated from women 
with recurrent spontaneous abortions. Compared with women with a normal pregnancy, 
the decidual CD4 cells from women with abortion show a defect in IL-4 and IL-10 
production (Piccinni et al., 1998). 
The antigens of the developing fetus are present at two interfaces as pregnancy progresses. 
The first interface is found between the invasive extravillous cytotrophoblast and maternal 
immune cells in the decidua. This local, tissue interface is of importance for immune 
adaptation during implantation. The second interface is that between the 
syncytiotrophoblast and the immune cells in maternal blood. This systemic interface is 
established at about the 10th gestational week and becomes increasingly important in the 
second half of pregnancy (Sargent et al., 2006a). Two contrary requirements influence the 
extent of invasion by fetal extravillous cytotrophoblast cells in the maternal decidua: the 
anchorage of the placenta to ensure fetal nutrition and the protection of the uterine wall 
against over-invasion (von Rango, 2008). If, due to excessive immunological tolerance and 
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acceptance of trophoblast cells, the uterine wall is over-invaded, pathologic conditions, such 
as placenta accreta, increta or percreta might develop (Bulmer, 1992). If the adequate 
invasion of the uterinal spiral arterioles by extravillous cytotrophoblasts does not occur, this 
sets up the conditions for placental hypoxia and oxidative stress that eventually triggers a 
maternal systemic inflammatory response, leading to clinical manifestations of preeclampsia 
(von Rango, 2008). 
This disorder is characterized by hypertension, proteinuria, edema and endothelial 
dysfunction generally evolving in the third trimester of pregnancy; however, it may also 
occur earlier. Although preeclampsia is quite common (i.e. it affects about 5-8% of all 
pregnancies globally), its clear cause and the mechanisms leading to immune dysfunction 
remain to be elucidated. Preeclampsia is estimated to be responsible for about 70,000 
maternal deaths each year worldwide (Walker, 2000). HELLP syndrome (consisting of 
hemolysis, elevated liver enzymes, low platelet count) and eclampsia are other 
manifestations of the same disorder. Although these conditions are generally coupled with a 
number of other symptoms (including headaches, abdominal pain, nausea, vomiting, 
abnormal vision, dyspnoe, anxiety, mental confusion, seizures), these manifestations are not 
necessarily more serious than preeclampsia. Besides a maternal systemic inflammatory 
response, signs of systemic vasoconstriction may also be observed in the mother in these 
pregnancy-associated disorders (Baumwell & Karumanchi, 2007). 
In preeclampsia, the anti-inflammatory state during the second and third trimesters 
develops insufficiently (Saito et al., 2007). An excessive maternal systemic inflammation is 
considered to be a dominant component in the pathogenesis of this pregnancy-specific 
disorder, since its important feature is the absence of Th2 skewness and thus the 
predominance of pro-inflammatory cytokines. Saito et al. reported on their observations 
regarding higher prevalence of IFN-γ and lower prevalence of IL-4-producing CD4 
lymphocytes among peripheral blood mononuclear cells (PBMCs) of preeclamptic women 
compared with healthy pregnant women. Furthermore, the percentage of Th1 and Th2 cells 
and the Th1/Th2 ratio correlated with IFN-γ and IL-4 secretion levels (Saito et al., 1999a). In 
another study, this group observed increased production of IL-2, IFN-γ and TNF-α by 
PBMCs in preeclampsia and, interestingly, a positive correlation between mean blood 
pressure and Th1 cytokines (Saito et al., 1999b). The shift to a predominant Th1-type 
immunity in preeclampsia is reinforced by other experiments on intracellular cytokine 
measurements in T and NK cells, as well as by the assessment of cytokine secretion levels of 
PBMCs isolated from preeclamptic patients. (Azizieh et al., 2005; Darmochwal-Kolarz et al., 
2002; Rein et al., 2002). 
3. The influence of galectin-1 on the Th1/Th2 cell ratio 
Previous studies demonstrated that soluble factors may also play a role in the development 
of the Th2 shift characteristic for healthy pregnancy. Such a factor is galectin-1, also 
produced by peripheral lymphocytes. Galectin-1, a 14 kDa protein, is a β-galactoside-
binding mammalian lectin. Within the immune system, it is expressed by activated T, B and 
NK cells as well as macrophages (Blaser et al., 1998; Koopman et al., 2003; Rabinovich et al., 
1998; Zuniga et al., 2001). Galectin-1 exerts immunoregulatory effects through various 
mechanisms. By binding to the cell surface glycoproteins, it inhibits T cell proliferation and 
induces apoptosis of activated Th1, Th17 and CD8 cells (Blaser et al., 1998; Perillo et al., 
1995; Toscano et al., 2007). Galectin-1 has been demonstrated in vitro to inhibit T cell 
 
Autoimmune Disorders – Pathogenetic Aspects 
 
450 
adhesion to the extracellular matrix and to abrogate the secretion of proinflammatory 
cytokines (Rabinovich et al., 1999a). Furthermore, in vivo administration of galectin-1 in 
experimental models of autoimmunity skewed the balance toward a Th2-dominant cytokine 
profile (Rabinovich et al., 1999b; Toscano et al., 2006). Recent data show that galectin-1 
promotes fetomaternal tolerance, since treatment with recombinant galectin-1 prevented 
fetal loss in an abortion-prone mouse model. The protective effect of galectin-1 was 
abrogated in regulatory T cell (Treg) depleted mice (Blois et al., 2007). Garin et al. showed 
that Tregs selectively up-regulate galectin-1 expression (Garin et al., 2007). Experiments 
using galectin-1 homozygous null mutant mice showed a reduced regulatory activity in 
Tregs and the blockage of galectin-1 binding diminished the inhibitory effects of human and 
mouse Treg cells (Rabinovich et al., 1998). These findings suggest that Tregs expressing 
galectin-1 may also support the acceptance of the fetus by maternal immune cells. 
In a recent study, we measured circulating galectin-1 and anti-galectin-1 autoantibody 
levels, as well as intracellular galectin-1 expression of unstimulated peripheral blood T and 
NK cells in healthy pregnancy and preeclampsia (Molvarec et al., 2011). Our findings 
indicate that the majority of CD4+ and CD8+ T cells and NK cells express intracellular 
galectin-1 in healthy pregnant women, while only a small fraction of them do so in healthy 
non-pregnant women. In preeclampsia, the proportion of galectin-1-expressing peripheral T 
and NK cells was markedly decreased compared with healthy pregnancy. However, 
circulating levels of galectin-1 and anti-galectin-1 autoantibodies were not altered in 
preeclamptic patients as compared to healthy pregnant women, nor were related to the 
proportions of galectin-1-expressing peripheral blood lymphocytes in any of the study 
groups. 
While Th1 and Th17 cells are susceptible to galectin-1-induced cell death, Th2 cells are 
protected from galectin-1 due to the differential sialylation of their cell surface 
glycoproteins. Indeed, galectin-1-deficient mice were shown to develop greater Th1 and 
Th17 responses (Toscano et al., 2007). Therefore, it is tempting to speculate that decreased 
production of galectin-1 by circulating T and NK cells might contribute to the development 
of the pro-inflammatory Th1 and Th17 immune responses, which are characteristic features 
of preeclampsia (Saito et al., 1999b; Toldi et al., 2011a). 
4. Regulatory T cells 
The recent discovery of a distinct T helper lymphocyte subset, referred to as Th17 cells, led 
to the transformation of the Th1/Th2 paradigm of immunity into a four-component model. 
This novel viewpoint incorporates Th1, Th2, Th17 and regulatory T cells (Tregs) as elements 
of a complex and mutually interacting network in the establishment of pregnancy-specific 
immune tolerance. Indeed, besides the imbalance of Th1 and Th2 cells, alterations of the 
prevalence of Th17 and Treg cells have been suggested to be of importance in the 
pathogenesis of adverse pregnancy outcomes (Saito, 2010). 
Tregs are important regulators of tolerance induction. During pregnancy, a systemic 
expansion of Tregs specific for paternally derived cells can be observed already at very early 
stages, indicating that their function is to protect paternally derived cells from immune 
rejection (Mjösberg et al., 2007). The prevalence of Tregs expands in the periphery and these 
cells are also present at significant numbers at the fetomaternal interface, preferentially in 
the maternal decidua. Sasaki et al. were the first to describe an increase in the CD4+ CD25+ 
Treg cell prevalence in decidual tissue in early human pregnancy (Sasaki et al., 2004). This 
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was supported by the works of Heikkinen et al. and Somerset et al. who observed an 
increase in the population of CD4+ CD25+ circulating Treg cells in early pregnancy and 
described a peak of this population during the second trimester and a subsequent gradual 
decrease to levels slightly higher than non-pregnant levels during the postpartum period 
(Heikkinen et al., 2004; Somerset et al., 2004). The tolerogenic impact of Tregs needs 
permanent antigen presentation without inflammatory co-stimulation. This explains the 
transient nature of the fetal tolerance and the fact that, especially during the first weeks of 
pregnancy, inflammatory infection of the mother may compromise pregnancy outcome. An 
expansion of Tregs in the decidua in healthy pregnant women accompanied by a low 
occurrence of Th17 cells was recently confirmed by Mjösberg et al. (Mjösberg et al., 2009). 
Furthermore, these authors propose that Tregs may be in charge of controlling the Th1 
activity found locally in healthy early pregnancy. 
Decreased Treg cell numbers during pregnancy are associated with immunological rejection 
of the fetus (Zenclussen, 2006). Sasaki et al. reported that spontaneous abortion cases are 
associated with lower systemic Treg levels when compared to normally developing 
pregnancies (Sasaki et al., 2004). A number of groups including ours demonstrated that the 
prevalence of peripheral Tregs is lower in preeclampsia compared with healthy pregnancy 
(Darmochwal-Kolarz et al., 2007; Sasaki et al., 2007; Steinborn et al., 2008; Toldi et al., 2008). 
Furthermore, Sasaki et al. reported that the prevalence of Tregs is lower not only in 
peripheral blood samples but also in deciduas of preeclamptic patients compared with 
healthy pregnant women (Sasaki et al., 2007). 
Tregs function in a delicate cellular network that includes inducer (myeloid and lymphoid 
dendritic cells) and target cells (CD4 and CD8 cells, NK cells and NKT cells) of Tregs (Fig. 1). 
Besides the peripheral prevalence of Tregs, we also characterized the prevalence of inducers 
and cellular targets of this T cell subset in preeclampsia and healthy pregnancy in the third 
trimester. We made efforts to find out whether the alteration of the number of Treg inducers 
is associated with the decreased number of Tregs. According to a previous study, the ratio 
of these cells is skewed toward the myeloid dendritic cells in the third trimester of 
preeclamptic pregnancy (Darmochwal-Kolarz et al., 2003). Theoretically, this may contribute 
to low Treg prevalence due to the lower Treg inducer capacity of myeloid dendritic cells 
than that of lymphoid dendritic cells (Ito et al., 2007). In our patients, however, the 
prevalence and ratio of myeloid and lymphoid dendritic cells did not differ, possibly 
indicating that dendritic cells are not responsible for low Treg numbers, at least in this stage 
of pregnancy. The lack of association may support the contribution of non-cellular factors, 
including pro-inflammatory cytokines such as TNF-α which has a direct inhibitory effect on 
suppressive Treg function in vitro (Valencia et al., 2006). TNF-α and other pro-inflammatory 
cytokine levels (such as IFN-γ, IL-6 and IL-12) are reportedly increased in PE (Rusterholz et 
al., 2007). Lower Treg numbers are not reflected in the proportion of NK, NK-T and 
activated CD4 and CD8 cells, at least at this stage of pregnancy. This does not exclude, 
however, that the function (such as the cytokine production pattern) of these cells is 
modified due to altered Treg numbers. 
Steinborn et al. further analyzed the prevalence of Tregs using various markers to identify 
this subset. Their analysis revealed two distinct Treg subsets that differed with regard to 
their FoxP3 and CD25 expression: CD4+ CD25+ FoxP3high+ and CD4+ CD25high+ FoxP3+ 
cells. When monitoring the two populations during healthy pregnancy and preeclampsia, 
they found a strong increase in the percentage of the CD4+ CD25+ FoxP3high+ Treg 
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(Based on Toldi et al., 2008.) 
Fig. 1. The cellular network of regulatory T cells (Tregs). Tregs are in connection with 
inducer and target cells through various mechanisms of activation and inhibition. 
population during the first and second trimesters, while in the third trimester, this Treg 
subset decreased gradually until term. The prevalence of CD4+ CD25+ FoxP3high+ Tregs 
correlated with suppressive capacity: Treg cells obtained from healthy pregnant women 
during the first and second trimester showed a two-fold higher suppressive activity than 
cells obtained in the third trimester or at term. The same correlation was true for patients 
affected by preeclampsia. The significantly diminished percentage of CD4+ CD25+ 
FoxP3high+ Tregs correlated with low suppressive capacity. In contrast to healthy 
pregnancy, the percentage of CD4+ CD25high+ FoxP3+ Treg cells was found to be increased 
in the circulation of preeclamptic women. In healthy pregnant women these cells expanded 
during the first trimester and reached maximum levels in the second trimester. Therefore, in 
preeclamptic women the population of CD4+ CD25high+ FoxP3+ Treg cells was particularly 
apparent, while the population of CD4+ CD25+ FoxP3high+ Tregs was significantly 
decreased. The authors proposed that CD4+ CD25+ FoxP3high+ and CD4+ CD25high+ 
FoxP3+ cell populations represent distinct Treg subsets, and that abnormalities in the 
balance of these subsets are associated with the presence of preeclampsia (Steinborn et al., 
2008). 
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5. The role of regulatory T cells in the process of tolerance induction 
Preeclampsia occurs more frequently in the first conception (Dekker & Sibai, 1998). 
However, preeclampsia appears to be a problem of primipaternity rather than 
primigravidity, since epidemiological data indicate that when the conception is with a new 
partner in multiparous mothers, the risk increases to the level seen in the first pregnancy 
(Robillard et al., 1993; Trupin et al., 1996). The symptoms of preeclampsia regress rapidly 
after delivery, suggesting that the exposure of the maternal immune system to the fetus and 
placenta, expressing paternal alloantigens, are of central importance in the pathogenesis. 
In donated spermatozoa, semen exposure does not occur and the fetus is a semi-allograft to 
the mother. The risk of preeclampsia in donated spermatozoa is very high (18.2%) (Salha et 
al., 1999), suggesting that semen exposure reduces the risk of preeclampsia. Soluble MHC 
class I antigens in the seminal fluid are taken up by vaginal and uterine epithelial cells, and 
these antigens might induce tolerance to cells expressing paternally derived MHC class I 
antigens. Indeed, semen triggers an influx of antigen-presenting cells into the female 
reproductive tract (Robertson et al., 2003). Usually, the fetus is a semi-allograft to the 
maternal host. The risk of preeclampsia is also increased in complete allograft-pregnant 
cases. In ovum donation, the antigens of the fetus are derived from the husband and the 
donor woman. Exposure to the husband’s semen is appropriately present. The risk of 
preeclampsia in ovum donation cases is high (16%), suggesting that the allografted fetus is a 
greater challenge for the maternal immune system, and is a risk factor for preeclampsia 
(Salha et al., 1999). In donated embryo transfer cases, the fetus is an allograft and semen 
exposure is not present. In this case, this risk of preeclampsia is even higher (33%), probably 
due to an additive effect of the allografted fetus and the absence of sperm exposure. 
Regulatory T cells, which induce tolerance to paternal antigens, may explain these 
epidemiological findings. Darmochwal-Kolarz et al. demonstrated that the levels of CD4+ 
CD45RO+ and CD8+ CD25+ cells are increased in preeclampsia, suggesting the activation of 
CD4+ and CD8+ T lymphocytes. It seems possible that the activation of T lymphocytes is 
associated with the deficiency of Tregs (Darmochwal-Kolarz etal., 2007). Before the first 
pregnancy, Treg cell numbers may increase due to seminal priming. Koelman et al. reported 
that soluble MHC class I antigens are present in the seminal fluid. It is well known that 
continuous oral exposure to antigens induces tolerance, called ‘oral tolerance’. Similarly, a 
continuous vaginal exposure to paternal soluble MHC class I antigens may induce tolerance 
to these antigens (Koelman et al., 2000). Robertson et al. suggest that insemination activates 
the maternal immune system and leads to hypo-responsiveness in T cells reactive with 
paternal alloantigens in mice (Robertson et al., 2003). This idea is supported by the 
epidemiological finding that condom users have a high risk for preeclampsia (Klonoff-
Cohen et al., 1989). 
The prevalence of Tregs is low in the mother before pregnancy (Fig. 2). This minor 
population of T cells, which reacts to paternal antigens and induces tolerance to them, 
expands after conception. When a threshold of prevalence is reached, sufficient immune 
tolerance to paternal antigens is achieved to ensure a healthy development of pregnancy. If 
the prevalence of Tregs does not reach the threshold, the risk for the development of 
preeclampsia is high. Subsequently, Tregs increase to a maximum in the second trimester of 
pregnancy and gradually decrease in the third trimester (Somerset et al., 2004). This finding 
is related to the clinical observation that the symptoms of preeclampsia generally appear in 
the third trimester, after 24 weeks of gestation. After delivery, the prevalence of Tregs may 
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Fig. 2. Alterations of maternal regulatory T cell (Treg) numbers during pregnancy. The 
prevalence of Tregs is low before pregnancy. When a threshold of Treg prevalence is 
reached during healthy pregnancy (black curve), the symptoms of preeclampsia do not 
develop. This is aided by seminal priming. If the prevalence of Tregs does not reach the 
threshold, the risk of preeclampsia is high (green curve). After the conception of a second 
pregnancy with the same partner, the number of Tregs increases more rapidly compared 
with the first pregnancy, independently from the initial prevalence of Tregs during the first 
pregnancy. However, in a second pregnancy with a new partner, the risk for developing 
preeclampsia is similar to that in the first pregnancy (blue curve). An increasing interval (> 
10 years) between the second and third deliveries was associated with an increasing risk of 
preeclampsia, and a lower prevalence of Tregs. 
rapidly decrease and at the beginning of a second pregnancy, there may be only a low 
number of Tregs present. Seminal priming may keep the number of these cells to a certain 
level (Fig. 2). After the conception of a second pregnancy with the same partner, the number 
of Tregs increases more rapidly compared with the first pregnancy, independently from the 
initial prevalence of Tregs (and the presence or lack of preeclampsia) during the first 
pregnancy. However, in a second pregnancy with a new partner, Tregs which induce 
tolerance to the new partner’s antigens may be very rare. Therefore, the risk for developing 
preeclampsia is similar to that in the first pregnancy. 
Skjaerven et al. reported that preeclampsia occurred in 3.9% of first pregnancies, 1.7% of 
second pregnancies, and 1.8% of third pregnancies when mothers had the same partner. 
Furthermore, an increasing interval between the second and third deliveries was associated 
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with an increasing risk of preeclampsia. When more than 10 years had passed after the 
previous delivery, the frequency rose to 3.0%. They also showed that a paternal change was 
not associated with an increased risk of preeclampsia after adjustment for the interval 
between births (Skjaerven et al., 2002). These findings might be explained by the population 
of Tregs. Tregs may gradually decrease and reach very low levels when more than 10 years 
have passed after the last delivery. A low level of these tolerance-inducing T cells may be 
maintained by seminal priming. However, in a subsequent pregnancy, some pregnant 
women may not be able to achieve adequate tolerance, resulting in an increased risk of 
preeclampsia. 
6. Th17 cells 
CD4+ IL-17+ (Th17) cells, this recently identified subpopulation of CD4 lymphocytes, 
originate from a developmental lineage that is distinct from both Th1 and Th2 cells. Th17 
cells produce IL-17 and other pro-inflammatory cytokines. IL-17 has an important role in the 
development of autoimmune disorders and in the induction and maintenance of chronic 
inflammation (Basso et al., 2009). The effect of Th17 cells on the inflammatory balance is 
opposed by Tregs. Th17 cells and Tregs originate from the same developmental lineage, 
distinct from both Th1 and Th2 cells. An exclusive dichotomy was observed in their 
generation: either Th17 or Treg cells develop from the ancestor cells depending on whether 
they are activated in the presence of transforming growth factor-β (TGF-β) or TGF-β plus 
inflammatory cytokines (Basso et al., 2009). 
In addition to their distinct role in the regulation of the inflammatory status, Th1, Th2, Th17 
and Treg cells mutually influence one another through the production of different cytokines. 
For instance, an increase in the Th17/Treg cell ratio may contribute to a shift towards the 
Th1 direction because IL-17 induces the production of other pro-inflammatory cytokines, 
such as that of IFN-γ (Afzali et al., 2007), while the inhibitory effect of Tregs on Th1 cells is 
decreased at the same time. 
In a previous study, Santner-Nanan et al. found that, besides a higher prevalence of Tregs, 
the percentage of Th17 cells is significantly decreased in the third trimester of healthy 
pregnancy compared with non-pregnant controls and preeclamptic patients. Consequently, 
the Th17/Treg cell ratio was significantly decreased in healthy but not in preeclamptic 
pregnancies. Thus, preeclampsia is associated with the absence of normal systemic skewing 
away from IL-17 production towards FoxP3 expression. Additionally, preeclamptic women 
had significantly higher levels of soluble endoglin, an inhibitor of TGF-β receptor signaling, 
which may bias towards IL-17 production (Santner-Nanan et al., 2009). 
In accordance with the above data, we also found that simultaneously with higher than 
normal Th17 numbers, the prevalence of Tregs is lower in PE, resulting in an elevated 
Th17/Treg ratio compared with uncomplicated pregnancy. The altered ratio of Th17/Treg 
cells may contribute to the shift towards the Th1 direction in preeclampsia. However, we 
could not detect a correlation between the prevalence of Th17 and Th1 cells (using the cell 
surface marker, CXCR3 for the identification of the latter subset). Thus, the effect of Th17 
cells and IL-17 on the inflammatory status is more likely to be exerted in a direct manner 
rather than through the modulation of the Th1/Th2 balance in preeclampsia (Toldi et al., 
2011a). 
The alterations of Th17 cells have been observed in other pregnancy-related disorders as 
well, suggesting that the balance of Th17 cells and Tregs and not only that of Th1 and Th2 
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cells has crucial effects on the inflammatory status in human pregnancy. Ito et al. recently 
demonstrated the importance of IL-17-producing cells in the pathomechanism of preterm 
labour (Ito et al., 2010). Nakashima et al. found that the prevalence of decidual IL-17-
producing cells is significantly higher in inevitable abortion cases (but not in missed 
abortion) than in normal pregnancy, indicating that these cells might be involved in the 
induction of inflammation in the late stage of abortion, but not in the early stage 
(Nakashima et al., 2010). In another study, Wang et al. showed that the prevalence of Th17 
cells in the peripheral blood and decidua is increased in unexplained recurrent spontaneous 
abortion patients (Wang et al., 2010). They observed that the expression of a Th17-associated 
factor, RAR-related orphan receptor gamma (ROR-γ or RORc), is also higher in peripheral 
blood lymphocytes and decidua of these patients. In a recent study, Jianjun et al. found that 
the mRNA level of this factor in PBMCs and decidua is elevated in preeclamptic patients 
when compared with healthy pregnant women (Jianjun et al., 2010). Therefore, the increased 
expression of this transcription factor may partly be responsible for the increased prevalence 
of Th17 cells in peripheral blood of preeclamptic patients. 
7. IL-17-producing CD8 and NK cells 
Although IL-17 was first identified in CD4 cells, later on other immune cells, including CD8 
and NK cells, were also shown to produce this cytokine (Passos et al., 2010; Shin et al., 1999). 
Emerging evidence suggests that these IL-17-producing lymphocyte subsets, especially NK 
cells, largely contribute to the inflammatory status during pregnancy. Sargent et al. 
proposed that the innate rather than the adaptive immune system controls immune 
regulation during human pregnancy, and that NK cells are of central importance to this 
process (Sargent et al., 2006b; Sargent et al., 2007). The aberrant activation of NK cells both 
systematically and locally in the placenta may be of major interest in the malfunction of 
immune tolerance and the pathogenesis of pregnancy-associated disorders. 
In our previously unpublished investigation, we measured the peripheral prevalence of IL-
17-producing cells in the CD4, CD8 and NK subsets and that of the IL-17 producing CD4, 
CD8 and NK cells in the overall lymphocyte population. We took peripheral blood samples 
from 24 healthy non-pregnant and 23 healthy pregnant age-matched women (with a median 
of 32 and 33 years, respectively), in the third trimester of pregnancy (with a median of 31 
weeks of gestation). Non-pregnant women were in the early follicular phase of the 
menstrual cycle (between cycle days 3 and 5), and none of them received hormonal 
contraception. Informed consent was obtained from all participating subjects. We separated 
the mononuclear cells from the samples and performed cell surface marker and intracellular 
cytokine staining. Finally, samples were measured on a flow cytometer. 
The prevalence of Th17 cells was lower among healthy pregnant compared with healthy 
non-pregnant women (2.8 [2.4-3.1] % vs. 3.2 [2.9-3.5] %). The prevalence of CD8+ IL-17+ 
(Tc17) cells among CD8 lymphocytes was higher in healthy pregnant than in healthy non-
pregnant samples (4.8 [3.6-6.2] % vs. 2.4 [1.7-3.7] %). The frequency of CD56+ IL-17+ (IL-17-
producing NK) cells was lower in healthy pregnant than in healthy non-pregnant samples 
(1.0 [0.6-1.2] % vs. 1.6 [1.1-2.5] %). 
We further analyzed the frequency of IL-17-producing CD4, CD8 and NK lymphocytes. 
After the initial assessment of the Th17, Tc17 and IL-17-producing NK cell prevalence 
among CD4, CD8 and NK cells, respectively (Fig. 3, graphs a-c), we also determined the 
prevalence of these subsets among the overall lymphocyte population (Fig. 3, graphs d-f) 
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along with the frequency of CD4+ IL-17-, CD8+ IL-17- and CD56+ IL-17- cells among the 
overall lymphocyte population (Fig. 3, graphs g-i). 
Our findings revealed two different mechanisms explaining the differing alterations 
observed in the prevalence of Th17 and Tc17 cells in the study groups. The alteration of 
CD4+ IL-17+ cell prevalence in the overall lymphocyte subset (Fig. 3, graph d) followed that 
seen among CD4 cells (Fig. 3, graph a), as the frequency of CD4+ IL-17- cells was 
comparable in both study groups (Fig. 3, graph g). Therefore, the prevalence of Th17 (CD4+ 
IL-17+) cells show absolute alterations, since Th17 cell numbers are altered not only in the 
CD4 subset, but also in the overall lymphocyte population. In contrast, Tc17 cell frequencies 
do not show significant difference if assessed among the overall lymphocyte population 
(Fig. 3, graph e); only the prevalence of CD8+ IL-17- cells differs between the study groups 
 
 
Fig. 3. Box-plots representing the prevalence of IL-17+ cells among CD4, CD8 and NK 
(CD56+) cells (graphs a-c) and in the overall lymphocyte population (ly) (graphs d-f), as well 
as the prevalence of IL-17- cells in the overall lymphocyte population (ly) (graphs g-i) in 
healthy non-pregnant (HNP) and healthy pregnant (HP) women. Horizontal line: median, 
box: interquartile range, whisker: range. * p values less than 0.05 were regarded significant. 
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(Fig. 3, graph h) and the direction of IL-17- cell alteration is the opposite of that seen at Tc17 
cell prevalence in the CD8 subset (Fig. 3, graph b). Therefore, the prevalence of Tc17 cells 
does not show absolute alterations, only relative ones, as a consequence of different CD8+ 
IL-17- cell frequencies in the study groups. The alteration of IL-17-producing NK cell 
prevalences among parent populations showed similar tendencies to that observed in case 
of CD4 cells. 
Of note, existing data are not consistent concerning the alterations of CD4 and CD8 cell 
frequencies during pregnancy. Tallon et al. found that CD4 cell numbers decrease in the 
second and third trimesters, while CD8 cells decrease during the third trimester (Tallon et 
al., 1984). Another study demonstrated that peripheral blood CD8 cells decreased during the 
first trimester, while CD4 cells decreased in the third trimester, with both populations 
increasing to non-pregnant values four months postpartum (Watanabe et al., 1997). The 
investigations by Kühnert et al. found no significant changes in the percentage CD4 and 
CD8 lymphocytes, nor in the CD4/CD8 ratio at any stage of pregnancy or postpartum. 
Based on our results, the apparent increase in Tc17 cell prevalence in healthy pregnancy 
compared with non-pregnant controls appears to be the consequence of decreased CD8+ IL-
17- cell frequency in this group, resulting in a higher proportion of Tc17 cells in the CD8 
subset. Since Tc17 cells have been described to have a lower cytotoxic activity in comparison 
with CD8+ IL-17- cells (Huber et al., 2009), the decrease in the latter subset and a relative 
increase in Tc17 prevalence may be regarded as part of the immunosuppressive mechanisms 
characterizing healthy pregnancy. 
In preeclampsia, our results show that in addition to CD4 cells, the prevalence of CD8 and 
NK cells that express IL-17 is also higher compared with healthy pregnant women. IL-17 
production by these lymphocyte subsets might contribute to the development of a systemic 
pro-inflammatory environment in PE (Toldi et al., 2011a). 
8. Lymphocyte activation kinetics 
Previous studies demonstrated that not only the prevalence of T lymphocyte subsets, but also 
their functionality is altered during pregnancy. For instance, calcium handling of T cells differs 
in healthy pregnancy and in the non-pregnant state. Previous reports indicate a sustained 
increase of basal intracellular calcium level in lymphocytes of healthy pregnant and 
preeclamptic women compared with non-pregnant women, with the highest levels in 
preeclampsia (Hojo et al., 1999; Thway et al., 2004; von Dadelszen et al., 1999). The availability 
of cytoplasmic free calcium has an important role in controlling the level of lymphocyte 
activation. We hypothesized that the elements of calcium handling of activated T lymphocytes, 
including lymphocyte potassium channels, may be affected in healthy pregnancy and 
preeclampsia compared to the non-pregnant state. Voltage-gated Kv1.3 channels along with 
calcium-dependent IKCa1 channels play a key role in the regulation of intracellular calcium 
homeostasis as they counterbalance the increase of cytoplasmic free calcium content in the 
course of lymphocyte activation. These channels grant the efflux of potassium from the 
cytoplasm, thus maintaining an electrochemical potential gradient needed for further calcium 
entry. Specific inhibition of these channels results in a diminished calcium influx into 
lymphocytes and a lower level of lymphocyte activation (Panyi et al., 2006). Our group 
characterized the activation-elicited calcium influx in the Th1, Th2, CD4 and CD8 lymphocyte 
subsets in healthy pregnant, preeclamptic and non-pregnant women and tested its alteration 
upon the inhibition of Kv1.3 and IKCa1 potassium channels (Toldi et al., 2011b). 
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Until recently, primarily single-cell techniques were applied to study the process of 
lymphocyte activation, and no reliable high-throughput method was available to investigate 
lymphocyte activation kinetics in more than one lymphocyte subsets simultaneously. The 
use of single-cell techniques are limited by the fact that they are not suitable for the 
description of kinetic processes in a complex cellular milieu that contains different types of 
interacting immune cells. For this purpose, we developed a novel, flow cytometry-based 
approach that enabled us to monitor lymphocyte activation simultaneously in different 
lymphocyte subtypes. 
For our measurements, we collected peripheral blood samples from healthy pregnant, 
preeclamptic and non-pregnant women. PBMCs were separated by a standard density 
gradient centrifugation. PBMCs were then incubated with conjugated anti-human surface 
marker monoclonal antibodies (CD4, CD8, CXCR3 for Th1 cells, CCR4 for Th2 cells) to 
identify lymphocyte subsets and were loaded with calcium sensitive Fluo-3 and Fura Red 
dyes to monitor alterations of the cytoplasmic free calcium level. PBMCs were divided into 
three vials. One vial was treated with margatoxin (MGTX), a selective blocker of the Kv1.3 
channel. Another vial was treated with a triarylmethane compound (TRAM), a specific 
inhibitor of the IKCa1 channel. The third vial was used as control. Measurements were 
initiated directly after the addition of 20 µg of phytohemagglutinin (PHA) as an unspecific 
activating stimulus. Cell fluorescence data were measured and recorded for 10 minutes in a 
kinetic manner on flow cytometer. 
Data acquired from the measurements were evaluated by fitting a double-logistic function 
for each recording (Kaposi et al., 2008). This function is used to describe measurements that 
have an increasing and a decreasing intensity as time passes. The software also calculates 
parameter values describing each function, such as the Maximum value (Max), the Time to 
reach maximum value (tmax), and the Area Under the Curve (AUC). These parameters 
represent different characteristics of lymphocyte calcium influx kinetics. The Maximum 
value represents the peak value of the calcium influx curve upon lymphocyte activation, 
thus it reflects the maximal amount of cytoplasmic free calcium in the course of activation. 
The Time to reach maximum value describes how soon the peak value of the calcium influx 
curve is reached. The Area Under the Curve describes the full amount of cytoplasmic free 
calcium during the whole period of lymphocyte activation and thus the magnitude of the 
elicited calcium response in general. 
Our results indicate that calcium influx kinetics in activated T lymphocytes markedly differs 
in healthy pregnancy compared with the non-pregnant state: AUC values of the calcium 
response are lower in healthy pregnancy in the Th1, CD4 and CD8 lymphocyte subsets (Fig. 
4). Based on this observation, it is reasonable to assume that the physiological immune 
tolerance towards fetal antigens in pregnancy is partly attributed to a lower calcium 
response. This hypothesis is further supported by the particular role of the impaired 
function of Th1 and CD8 lymphocyte subsets in maternal immune tolerance. On contrary to 
Th1 cells, the activation induced calcium response of the Th2 subset is not decreased 
compared with the non-pregnant state. The decreased activation of the Th1 subset (reflected 
by low AUC values in our study) and the lack of decrease in Th2 cells may partly be 
responsible for the well established Th2 skewness in healthy pregnancy. 
Unlike in healthy pregnancy, we could not detect a difference in the AUC values of calcium 
influx kinetics of Th1 and CD8 cells in preeclampsia compared to non-pregnant women (Fig. 
4). The absence of calcium influx characteristics specific for healthy pregnancy suggests that 
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Fig. 4. Calcium influx kinetics of peripheral Th1 lymphocytes isolated from healthy non-
pregnant (HNP), healthy pregnant (HP) and preeclamptic (PE) women (without lymphocyte 
potassium channel inhibitor treatment). Calcium influx is lower in healthy pregnancy 
compared with the non-pregnant state and preeclampsia. 
this element may associate with the impaired maternal immune tolerance present in 
preeclampsia, since the calcium influx kinetics is comparable to that seen in non-pregnant 
samples. Indeed, the maintained activation properties of Th1 lymphocytes in preeclamptic 
patients may contribute to the lack of Th2 dominance associated with normal pregnancy. 
Similarly to the Th1 subset, CD8 cells in preeclampsia are also characterized by the lack of 
suppressed activation kinetics. Thus the decrease of cytotoxic activity observed in healthy 
pregnancy (Malinowski et al., 1994) is not present in preeclampsia. Interestingly, tmax values 
were decreased in Th2 and CD4 cells in preeclampsia compared with healthy pregnancy. 
This finding may indicate an increased reactivity of lymphocytes in preeclampsia, possibly 
reflecting an elevated responsiveness of T lymphocytes due to the ongoing maternal 
systemic inflammation. 
Since Kv1.3 and IKCa1 potassium channels significantly influence the calcium response 
elicited upon lymphocyte activation, we tested their expression and function in healthy 
pregnancy and preeclampsia. According to comparable fluorescence values of the samples 
stained with specific antibodies against Kv1.3 channels, their expression is not altered in any 
of the investigated T lymphocyte subsets. Therefore, the differences detected between 
calcium influx of non-pregnant, healthy pregnant and preeclamptic lymphocytes upon 
treatment with specific inhibitors of the potassium channels is probably due to the altered 
function, and not to the altered expression of these channels. 
Our results suggest that the overall lymphocyte population and particularly the CD4 subset 
are sensitive to MGTX and TRAM inhibition in each investigated study group, indicating 
that both Kv1.3 and IKCa1 channels play an important regulatory role in calcium influx. 
This is reflected by the decrease of the AUC and Max values compared with the respective 
samples where no inhibitors were applied. However, the sensitivity of calcium influx 
measured in other lymphocyte subsets shows clear variability. It is of particular interest that 
calcium influx of Th2 lymphocytes in healthy pregnancy was insensitive to potassium 
channel inhibition, while calcium influx decreased significantly in non-pregnant samples 
upon treatment with the specific channel blockers. Of note, Th2 lymphocytes in 
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preeclampsia presented with non-pregnant-like characteristics, and were also sensitive to 
MGTX and TRAM treatment. Since the regulatory function of Kv1.3 and IKCa1 channels on 
calcium influx appears to be limited in healthy pregnant samples (as the inhibition of these 
channels did not result in a decrease of the AUC and Max values), it is tempting to speculate 
that this may be an element contributing to the Th2 shift present in healthy pregnancy, but 
absent in preeclampsia. This hypothesis may be supported by reports suggesting that the 
shape of calcium influx influenced by potassium channel functions may determine the 
cytokine production profile of helper T lymphocytes (Dolmetsch et al., 1998; Fanger et al., 
2000). 
Interestingly, other differences were also observed between healthy pregnancy and 
preeclampsia. While calcium influx in CD8 and Th1 lymphocytes was resistant to potassium 
channel inhibition in preeclamptic samples, that of healthy pregnant lymphocytes was 
sensitive. Similarly to Th2 cells, while it is unclear whether the resistance of Th1 
lymphocytes to potassium channel inhibition is reflected in their function, the insensitivity 
of the Th1 subset to the inhibition of regulatory lymphocyte potassium channels in 
preeclampsia may be linked to the Th1 skewness. 
Our findings suggest that there is a characteristic pattern of calcium influx in T lymphocytes 
and its sensitivity to potassium channel inhibition in normal pregnancy that is missing in 
preeclampsia. This raises the notion that T lymphocyte calcium handling may have a role in 
the development of the pregnancy-specific immune tolerance. 
9. The association between preeclampsia and autoimmunity 
Considering the immunological alterations described in preeclampsia, one may notice 
characteristic similarities in the etiology shared with autoimmune disorders. As a result of 
the impaired immune tolerance, preeclampsia is distinguished by many features typically 
seen in autoimmune diseases, or in association with autoimmune reactions. This does not 
mean that preeclampsia should be considered an autoimmune condition. However, it does 
suggest that abnormal autoimmune processes play an important part in the pathogenesis of 
preeclampsia. An interpretation of preeclampsia can be found in analogies to organ rejection 
after allograft transplantation and in graft-versus-host disease (GVHD); like preeclampsia, 
these conditions are also characterized by a multitude of systemic symptoms. The 
similarities with acute organ rejection and GVHD are paralleled by the notion that if a 100% 
allograft can elicit autoimmune responses during organ transplantation, one should not be 
surprised that a 50:50 autograft-allograft can do the same thing. This recognition may lead to 
better clinical approaches to preeclampsia and thereby to better diagnosis and treatment 
(Gleicher, 2007). 
The clinical relationship between autoimmune diseases and pregnancy is unique. No other 
diseases are characterized by an exacerbation pattern that is particularly pronounced in the 
peripartum and postpartum periods (Gleicher et al., 1993). A recently recognized example is 
peripartum cardiomyopathy, with disease flares from late pregnancy up to approximately 
three months postpartum (Ansari et al., 2002). Preeclampsia is also characterized by a 
peripartal exacerbation pattern, with the majority of cases developing after 36 weeks of 
gestation. 
Besides the cellular abnormalities already discussed, autoantibody abnormalities have also 
been reported in association with preeclampsia. So far, a number of autoantibodies have 
been implicated in the pathogenesis (Branch et al., 1994; Milliez et al., 1990; Rappaport et al., 
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1990; Yamamoto et al., 1993). The most important one of them appears to be an agonistic 
autoantibody against the angiotensin II type 1 receptor (Wallukat et al., 1999). Moreover, as 
in classical autoimmune diseases, more severe preeclampsia appears to result in more 
autoantibody abnormalities (El-Roeiy et al., 1991). Evidence suggests that classical, 
nonorgan-specific autoantibodies, such as antiphospholipid antibodies, are characteristic of 
preeclampsia, and especially in its more severe clinical expression (El-Roeiy et al., 1991; 
Yamamoto et al., 1993). Dekker et al. therefore recommended active laboratory surveillance 
for patients at risk (Dekker et al., 1995). 
Both GVHD-related and classical autoimmune conditions often improve upon treatments 
that have been found successful also in preeclampsia and HELLP syndrome. Three 
examples are the treatment with corticosteroids, removal of autoantibody abnormalities via 
plasmapheresis, and the competitive binding of autoantibodies with intravenous 
immunoglobulin (Katz et al., 1990; Martin et al., 1990; Martin et al., 2006). 
Considering the significant degree of bidirectional cell traffic during pregnancy, one can 
speculate that, in analogy to GVHD, the autoimmune phenomena, seen in association with 
preeclampsia, may be immune responses by fetal lymphocytes to epitopes shared by mother 
and fetus. Alternatively, the autoimmune response in preeclampsia could be distinct from 
that in GVHD, and purely autoimmune in nature. This would then represent an immune 
response solely against maternal self-epitopes on fetal cells that have entered the maternal 
circulation. A number of observations indicate that the paternal genotype is of importance 
in that regard. For instance, the more similar the paternal histocompatibility complex is to 
that of the mother, the more likely a miscarriage will occur due to increased autoantigenity 
(Kishore et al., 1996). The fetus is not only an allograft but also an autograft. Since one half of 
the fetus is maternally derived in its antigenicity, the maternal immune system also faces an 
unprecedented autoimmune load. At no other period in life needs the maternal immune 
system to be prepared for autoimmune challenges of this extent. The immunological 
adjustment to pregnancy, therefore, does not only involve the development of tolerance to 
the paternal allogenic, but also to the maternal autoimmunogenic components of the fetus. 
Autoimmune phenomena are mostly seen in two periods of pregnancy: during early 
conception and the peripartum period. In early conception, abnormal immune activation 
may be coupled with pregnancy loss. Later stage presentation appears to be associated with 
preeclampsia. Indeed, women with early autoimmune activation, who (with treatment) do 
not miscarry, demonstrate a greatly increased risk for preeclampsia (Gleicher et al., 1993). 
This observation supports the idea of a common alloimmune or autoimmune etiology for 
both of these conditions. It has also been suggested that an analogy might exist not only 
between chronic graft rejection and preeclampsia, but also between acute graft rejection and 
recurrent abortion (Wilczyński, 2006). 
Accepting the concept that preeclampsia is characterized by autoimmune phenomena may 
have benefits for better diagnosis and treatment. For example, autoimmune phenomena 
usually go through pre- or subclinical stages before their clinical manifestation. Laboratory 
markers are often already detectable at those early stages (Davidson & Diamond, 2001). If 
the autoimmune phenomena of preeclampsia were to follow a similar pattern, earlier 
diagnosis and specific treatment might become possible. 
10. Conclusion 
T lymphocytes play a central role in the development of the maternal immune tolerance 
during pregnancy. Pathologic alterations of T cells in prevalence and functionality 
 
T Lymphocyte Characteristics and Immune Tolerance During Human Pregnancy 
 
463 
contribute to the onset of pregnancy-related disorders, and might represent a possible future 
target for therapeutic intervention. 
It has been recognized for many years that the prevalence of distinct T cell subpopulations 
are subject to a characteristic adjustment during pregnancy in order to facilitate the specific 
needs raised by the developing fetus. The course of this adjustment may be insufficient in 
pregnancy-related disorders. Recently, it has been demonstrated that not only cell numbers, 
but also the functionality of cells needs to go through specific alterations to help the 
maternal immune system in acquisition of the pregnancy-specific tolerance. As an example, 
we have demonstrated that there is a characteristic pattern of calcium influx in T 
lymphocytes and its sensitivity to lymphocyte potassium channel inhibition in healthy 
pregnancy that is missing in preeclampsia, raising the notion that T lymphocyte calcium 
handling may have a role in the distinctive immune status of uncomplicated pregnancy. 
Further research needs to be carried out applying different methods to identify additional 
factors involved in these alterations. This approach might lead to better strategies for the 
prevention and treatment of adverse pregnancy outcomes, facilitating the development and 
maintenance of immune tolerance needed for healthy pregnancy. 
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